ライフサイエンスコーパス: colony-stimulating factor

1 onocyte chemotactic protein-1 and macrophage colony-stimulating factor).

2 ycol) modified recombinant human granulocyte-colony stimulating factor.

3 r-like phenotype with granulocyte-macrophage colony-stimulating factor.

4 ancement of IL-10 and granulocyte-macrophage colony-stimulating factor.

5 osis factor-alpha and granulocyte macrophage colony-stimulating factor.

6 of responsiveness to granulocyte-macrophage colony-stimulating factor.

7 atments except CTLA-4/granulocyte macrophage colony-stimulating factor.

8 FN-gamma, IL-17A, and granulocyte-macrophage colony-stimulating factor.

9 uclear factor kappa-B ligand, and macrophage colony-stimulating factor.

10 rial infection, starvation and by macrophage colony-stimulating factor.

11 if) ligand 2, and the granulocyte macrophage colony-stimulating factor.

12 reatment or genetic deficiency of macrophage colony-stimulating factor.

13 sis factor alpha, and granulocyte-macrophage colony-stimulating factor.

14 and possibly also for granulocyte-macrophage colony-stimulating factor.

15 sus intravenous antibiotics; and addition of colony-stimulating factors.

16 necrosis factor inhibitors, and granulocyte colony-stimulating factors.

17 Viral-mediated knockdown of neuronal colony stimulating factor 1 (CSF1) was used to modulate

18 Depletion of immunosuppressive, colony stimulating factor 1 receptor (CSF-1R)-dependent

19 Mutations in the colony stimulating factor 1 receptor (CSF1R) have recent

20 ng macrophages through its inhibition of the colony stimulating factor 1 receptor (CSF1R).

21 show that treatment with the pharmacological colony stimulating factor 1 receptor inhibitor PLX5622 s

22 io lacked such projections, concomitant with Colony stimulating factor 1-dependent changes in xanthop

23 ted with gamma interferon (IFN-gamma) DNA or colony-stimulating factor 1 (CSF-1) DNA prior to ocular

24 Colony-stimulating factor 1 (CSF-1), the cytokine acting

25 clear that alloantibody can, in concert with colony-stimulating factor 1 (CSF-1)-dependent donor macr

26 ly suppresses OC differentiation by limiting colony-stimulating factor 1 (CSF-1)-dependent proliferat

27 n neutralizing antibodies against macrophage colony-stimulating factor 1 (CSF1 or MCSF) or F4/80.

28 Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in m

29 l nerve injury induced de novo expression of colony-stimulating factor 1 (CSF1) in injured sensory ne

30 et of inflammatory response genes, including colony-stimulating factor 1 (CSF1), a central regulator

31 ed, is characterised by an overexpression of colony-stimulating factor 1 (CSF1), and is usually cause

32 nduced the tumor cells to express macrophage colony-stimulating factor 1 (M-CSF1 or CSF1) and other c

33 In response to liver injury, colony-stimulating factor 1 drives early monocyte-mediat

34 Conversely, incubation of colony-stimulating factor 1 macrophages with E2 increase

35 tumour-to-tumour heterogeneity, response to colony-stimulating factor 1 receptor (CSF-1R) blockade a

36 scriptional events and signals downstream of colony-stimulating factor 1 receptor (CSF-1R) that contr

37 on of macrophages induces phosphorylation of colony-stimulating factor 1 receptor (CSF-1R), which con

38 y discovered that microglia are dependent on colony-stimulating factor 1 receptor (CSF1R) signaling f

39 croglia in the healthy adult mouse depend on colony-stimulating factor 1 receptor (CSF1R) signalling

40 hanism is regulated by the activation of the colony-stimulating factor 1 receptor (CSF1R), thus provi

41 In contrast, colony-stimulating factor 1 receptor blockade diminished

42 has revealed a novel mutation p.R782G in the Colony-Stimulating Factor 1 Receptor gene (CSF1R).

43 hed in mice depleted of microglia by using a colony-stimulating factor 1 receptor inhibitor.

44 cked macrophage function in ID8 mice using a colony-stimulating factor 1 receptor kinase inhibitor (G

45 results of studies inhibiting the macrophage colony-stimulating factor 1 receptor,whereas the CD11b(+

46 y autosomal dominant mutations in the CSF1R (colony-stimulating factor 1) gene.

47 etween interleukin 1 receptor antagonist and colony-stimulating factor 1, colony-stimulating factor 2

48 fibrosis, illustrating the critical role of colony-stimulating factor 1-dependent monocyte/macrophag

49 motif ligand 2 that stimulated migration of colony-stimulating factor 1-differentiated macrophages.

50 The cytokine colony stimulating factor-1 (CSF-1) acts as an important

51 tion has increased expression of xanthogenic Colony Stimulating Factor-1 (Csf1).

52 We found that PLX3397, an inhibitor of colony stimulating factor-1 receptor (CSF-1R), blocks gl

53 been found to be caused by mutations in the colony stimulating factor-1 receptor (CSF1R) gene.

54 Interestingly, colony stimulating factor-1 receptor (CSF1R) is signific

55 dministered a dietary inhibitor (PLX5622) of colony stimulating factor-1 receptor (CSF1R) to deplete

56 er fracture with the pro-macrophage cytokine colony stimulating factor-1 significantly enhanced soft

57 Colony-stimulating factor-1 (CSF-1) is expressed by kidn

58 the macrophage attractant and growth factor colony-stimulating factor-1 (CSF-1).

59 Patient data suggest that colony-stimulating factor-1 (CSF1) and its receptor (CSF

60 Inhibition of TAM recruitment using an anti-colony-stimulating factor-1 antibody compromised the sur

61 The colony-stimulating factor-1 receptor (CSF-1R) kinase reg

62 ession and can be targeted via inhibition of colony-stimulating factor-1 receptor (CSF-1R) to regress

63 tiation is mediated by signaling through the colony-stimulating factor-1 receptor (CSF-1R) which is n

64 g in the E13.5 mouse fetal liver express the colony-stimulating factor-1 receptor (CSF1R), previously

65 We then used the colony-stimulating factor-1 receptor inhibitor PLX5622 t

66 e metastatic site and granulocyte-macrophage colony-stimulating factor (125 mug/m(2) subcutaneously i

67 antagonist and colony-stimulating factor 1, colony-stimulating factor 2 and interleukin 17F, without

68 The colony-stimulating factor 2 receptor beta subunit (Csf2r

69 052 controls for frameshift mutations in the colony-stimulating factor 2-receptor beta common subunit

70 day) on days 2-5 plus granulocyte macrophage colony-stimulating factor (250 mug/m(2) per dose) subcut

71 in 6, interleukin 10 receptor alpha subunit, colony stimulating factor 3 receptor and toll-like recep

72 ereas expression of the neutrophil activator colony-stimulating factor 3 (CSF3) was suppressed in CD3

73 a high prevalence (>80%) of mutations in the colony-stimulating factor 3 receptor (CSF3R).

74 interleukin-6, tumour necrosis factor-a and colony-stimulating factor 3), and antiinflammatory marke

75 nterleukin-3, interleukin-6, and granulocyte colony-stimulating factor (5 GFs) either alone or combin

76 IMA901 (4.13 mg) and granulocyte macrophage colony-stimulating factor (75 mug), with one dose of cyc

77 inflammatory markers, including granulocyte colony-stimulating factor (adjusted OR 2.8 [95% CI 1.3-6

78 olves subcutaneous injections of granulocyte-colony-stimulating factor/AMD3100 to mobilize HSPCs from

79 ed CXCL12 induction and improved granulocyte-colony stimulating factor and ischemia-induced mobilizat

80 rophages in adulthood and raised granulocyte-colony stimulating factor and neutrophil counts/activity

81 macrophages easily in vitro with macrophage colony-stimulating factor and human serum.

82 reduced responses to granulocyte-macrophage colony-stimulating factor and markedly decreased activit

83 angerin and CD1a with granulocyte-macrophage colony-stimulating factor and transforming growth factor

84 a, interleukin-6, and granulocyte macrophage colony-stimulating factor) and hypothermia at 18 hours.

85 to antagonize GM-CSF (granulocyte macrophage colony-stimulating factor) and IL-2 (interleukin-2), two

86 and presumably secreted), G-CSF (granulocyte-colony-stimulating factor) and MMP2 (matrix metalloprote

87 y stimulating factor, granulocyte-macrophage colony-stimulating factor, and C-reactive protein at enr

88 roxidase, IL-8, IL-1alpha, IL-6, granulocyte colony-stimulating factor, and GM-CSF levels.

89 BAL fluid IL-1alpha, IL-6, IL-8, granulocyte colony-stimulating factor, and GM-CSF levels.

90 ecrosis factor alpha, granulocyte-macrophage colony-stimulating factor, and granzyme B), and they wer

91 h-regulated oncogene, granulocyte macrophage colony-stimulating factor, and IL-1beta.

92 ein 1alpha and 1beta, granulocyte-macrophage colony-stimulating factor, and interferon-gamma were sig

93 entrations of interleukin-1beta, granulocyte colony-stimulating factor, and matrix metalloproteinase

94 CR1 up-regulation, whereas CCL1, granulocyte colony-stimulating factor, and MIP1alpha were required f

95 matopoietic IL-7, and granulocyte macrophage colony-stimulating factor, and regulatory IL-10 were mea

96 scular cell adhesion molecule-1, granulocyte colony-stimulating factor, and soluble Fas.

97 17, interferon gamma, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor tha

98 Interferon-gamma and granulocyte-macrophage colony-stimulating factor are requisite factors in the t

99 Recent reports have identified hematopoietic colony-stimulating factors as important regulators of tu

100 dendritic cells, and granulocyte-macrophage colony-stimulating factor at the same site.

101 us mycobacteria; anti-granulocyte macrophage colony-stimulating factor autoantibodies and cryptococca

102 B-cell depletion and granulocyte-macrophage colony-stimulating factor blockade.

103 Neutralizing granulocyte-colony stimulating factor blocked susceptibility to dise

104 17, gamma interferon, granulocyte-macrophage colony-stimulating factor) by CD4(+) and CD8(+) T cells,

105 ilized with cyclophosphamide and granulocyte colony-stimulating factor, collected by peripheral blood

106 fter stimulation with granulocyte-macrophage colony-stimulating factor, compared with cells transfect

107 , influenced human monocyte responses to the colony-stimulating factors CSF-1 and CSF-2 in vitro.

108 Colony-stimulating factor (CSF)-1 and interleukin (IL)-3

109 nnate immunity-related markers calprotectin, colony-stimulating factor (CSF)-1, macrophage migration

110 We have previously shown that macrophage colony-stimulating factor (CSF-1; M-CSF) directly instru

111 ver macrophages are controlled by macrophage colony-stimulating factor (CSF1).

112 enhanced bacterial replication in macrophage colony-stimulating factor-differentiated macrophages mor

113 rophages more than in granulocyte-macrophage colony-stimulating factor-differentiated macrophages.

114 hematopoietic stress, including granulocyte colony-stimulating factor, do not increase the mutation

115 ransplantation, a combination of granulocyte colony-stimulating factor, erythropoietin, aminocaproic

116 il 750 mg/m2 IV over 5 days with granulocyte colony-stimulating factor, every 3 weeks).

117 service, meropenem, and adjuvant granulocyte colony-stimulating factor for confirmed melioidosis seps

118 ective effects of the cytokines, granulocyte-colony stimulating factor (G-CSF) and stem cell factor (

119 mechanism in which tumor-derived granulocyte-colony stimulating factor (G-CSF) directs expansion and

120 ed cases, there is evidence that granulocyte-colony stimulating factor (G-CSF) in patients with glyco

121 Granulocyte colony stimulating factor (G-CSF) may enhance recovery f

122 e was obtained by reducing human granulocyte-colony stimulating factor (G-CSF) prior to MS/MS and MS(

123 Using a granulocyte-colony stimulating factor (G-CSF) receptor knockout mous

124 s: antithymocyte globulin (ATG), granulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidas

125 A, beta2-microglobulin (beta2m), granulocyte colony stimulating factor (G-CSF), and three monoclonal

126 -activating protein 78 (ENA-78), granulocyte colony stimulating factor (G-CSF), granulocyte macrophag

127 ammatory factors including IL-8, granulocyte-colony stimulating factor (G-CSF), IL-33, IL-11, IL-1alp

128 samples, and downregulated upon granulocyte-colony stimulating factor (G-CSF)- mediated granulocytic

129 hood due to the up-regulation of granulocyte-colony stimulating factor (G-CSF); these effects are rev

130 ify the proinflammatory cytokine granulocyte-colony-stimulating factor (G-CSF or Csf-3) as a key medi

131 tment when forced into cycle via granulocyte colony-stimulating factor (G-CSF) administration.

132 ation of the therapeutic protein granulocyte colony-stimulating factor (G-CSF) against storage at 4 d

133 on and migration by antagonizing granulocyte colony-stimulating factor (G-CSF) and chemokine receptor

134 ions from donors stimulated with granulocyte colony-stimulating factor (G-CSF) and dexamethasone.

135 essed the safety and efficacy of granulocyte colony-stimulating factor (G-CSF) and haemopoietic stem-

136 uced severely reduced amounts of granulocyte colony-stimulating factor (G-CSF) and of nitric oxide (N

137 nse to systemic up-regulation of granulocyte colony-stimulating factor (G-CSF) and the ELR(+) CXC che

138 potential protective effects of granulocyte colony-stimulating factor (G-CSF) and underlying mechani

139 ispensable for the production of granulocyte colony-stimulating factor (G-CSF) by hypoxic breast canc

140 10(9)/L, and median ANC without granulocyte colony-stimulating factor (G-CSF) during follow-up was 0

141 the concurrent administration of granulocyte colony-stimulating factor (G-CSF) enhanced RT-mediated a

142 inherent disadvantages of using granulocyte colony-stimulating factor (G-CSF) for hematopoietic stem

143 Granulocyte colony-stimulating factor (G-CSF) has been shown to incr

144 Granulocyte colony-stimulating factor (G-CSF) is a regulator of neut

145 Human granulocyte colony-stimulating factor (G-CSF) is an endogenous glyco

146 Granulocyte colony-stimulating factor (G-CSF) is used clinically to

147 Granulocyte colony-stimulating factor (G-CSF) is widely used clinica

148 ttractive protein 1 (MCP-1), and granulocyte colony-stimulating factor (G-CSF) levels in the amniotic

149 te globulin (ATG) plus pegylated granulocyte colony-stimulating factor (G-CSF) preserves beta-cell fu

150 rpose To describe outcomes after granulocyte colony-stimulating factor (G-CSF) prophylaxis in patient

151 lood circulation by the cytokine granulocyte colony-stimulating factor (G-CSF) through complex mechan

152 cells (BMMC) and the ability of granulocyte colony-stimulating factor (G-CSF) to mobilize endogenous

153 xpression in neuronal cells, and granulocyte colony-stimulating factor (G-CSF) was chosen, due to its

154 ients mobilized with hydroxyurea+granulocyte colony-stimulating factor (G-CSF), G-CSF, Plerixafor, or

155 MIP-1beta, granulocyte colony-stimulating factor (G-CSF), interleukin-12/23 (IL

156 8, gamma interferon (IFN-gamma), granulocyte colony-stimulating factor (G-CSF), monocyte chemoattract

157 and NOD1 synergistically induced granulocyte colony-stimulating factor (G-CSF), which was required fo

158 1 year after transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized blood cells

159 ed cells, promoting an excessive granulocyte colony-stimulating factor (G-CSF)-regulated neutrophilic

160 at appears in the circulation of granulocyte colony-stimulating factor (G-CSF)-treated donors (GDs) c

161 a standard multi-day regimen of granulocyte colony-stimulating factor (G-CSF).

162 HSC) mobilization in response to granulocyte colony-stimulating factor (G-CSF).

163 Human granulocyte colony-stimulating factor (GCSF) is a well-known cytokin

164 we report that human granulocyte macrophage-colony stimulating factor (GM-CSF) can sensitize the per

165 e mechanisms by which granulocyte/macrophage-colony stimulating factor (GM-CSF) signaling normally ma

166 d with Ipilimumab and granulocyte macrophage colony stimulating factor (GM-CSF) was presented in the

167 ating factor (G-CSF), granulocyte macrophage colony stimulating factor (GM-CSF), IL-8, IL-18, monocyt

168 or alpha (TNF-alpha), granulocyte macrophage colony stimulating factor (GM-CSF), interleukin 6 (IL-6)

169 ends on production of granulocyte macrophage-colony stimulating factor (GM-CSF), which recruits and m

170 n-gamma (IFN-gamma) and granulocyte monocyte colony stimulating factor (GM-CSF).

171 Granulocyte-macrophage colony-stimulating factor (GM-CSF or Csf-2) is a pro-inf

172 terleukin (IL)-12 and granulocyte-macrophage colony-stimulating factor (GM-CSF) (oAd) and DCs for sus

173 kin (IL)-3, IL-5, and granulocyte macrophage-colony-stimulating factor (GM-CSF) and can result from e

174 e hydrogel containing granulocyte macrophage colony-stimulating factor (GM-CSF) and CpG ODN1826 (CpG)

175 e with breast cancer: granulocyte macrophage colony-stimulating factor (GM-CSF) and matrix metallopep

176 valuate the effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) and peptide vaccinati

177 dults, including anti-granulocyte macrophage colony-stimulating factor (GM-CSF) autoantibodies with c

178 nterleukin-23 (IL-23)-granulocyte macrophage colony-stimulating factor (GM-CSF) axis in colitis.

179 ed productions of the granulocyte-macrophage colony-stimulating factor (GM-CSF) by central nervous sy

180 CL-3 (MIP-1alpha) and granulocyte-macrophage colony-stimulating factor (GM-CSF) can enhance the immun

181 ave demonstrated that granulocyte macrophage colony-stimulating factor (GM-CSF) can function as a key

182 erleukin 4 (IL-4) and granulocyte macrophage colony-stimulating factor (GM-CSF) drive dendritic cell

183 ith cytokines such as granulocyte-macrophage colony-stimulating factor (GM-CSF) enhances eosinophil m

184 Benefits of granulocyte-macrophage colony-stimulating factor (GM-CSF) for improving walking

185 g evidence shows that granulocyte macrophage colony-stimulating factor (GM-CSF) has progression-promo

186 t mutant Shp2 induces granulocyte macrophage-colony-stimulating factor (GM-CSF) hypersensitivity and

187 an essential role for granulocyte/macrophage colony-stimulating factor (GM-CSF) in orchestrating thes

188 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a medicinally impo

189 Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pleiotropic cyto

190 Here we show that granulocyte macrophage colony-stimulating factor (GM-CSF) is a triggering molec

191 inflammatory cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) is EGFR dependent in

192 st that the increased granulocyte-macrophage colony-stimulating factor (GM-CSF) level in the EDM-TTF-

193 ng antibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF) or tumor necrosis fac

194 d the pro-M1 cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) plus blockade of the

195 Granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by T helper

196 e show that deficient granulocyte-macrophage colony-stimulating factor (GM-CSF) production altered mo

197 ing factor (M-CSF) or granulocyte macrophage colony-stimulating factor (GM-CSF) resembled in vivo inf

198 atment or blockade of granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling in SFB-colo

199 piratory defenses via granulocyte-macrophage colony-stimulating factor (GM-CSF) signaling, which stim

200 c fibroblasts produce granulocyte/macrophage colony-stimulating factor (GM-CSF) that acts locally and

201 hemocyanin (KLH) plus granulocyte macrophage colony-stimulating factor (GM-CSF) to a control immunoth

202 in tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) to enhance systemic a

203 arrow (BM) cells with granulocyte-macrophage colony-stimulating factor (GM-CSF) to generate BM-derive

204 hypotheses that human granulocyte-macrophage colony-stimulating factor (GM-CSF), a clinically used cy

205 vity of JMML cells to granulocyte macrophage-colony-stimulating factor (GM-CSF), a unifying character

206 Granulocyte-macrophage colony-stimulating factor (GM-CSF), mainly produced by M

207 he chemokine CCL2 and granulocyte-macrophage colony-stimulating factor (GM-CSF), respectively.

208 with soluble ligands granulocyte macrophage colony-stimulating factor (GM-CSF), transforming growth

209 rs in the presence of granulocyte/macrophage colony-stimulating factor (GM-CSF), we used GM-CSF-defic

210 72 strongly augmented granulocyte-macrophage-colony-stimulating factor (GM-CSF)-induced differentiati

211 ges (MDMs), including granulocyte macrophage colony-stimulating factor (GM-CSF)-polarized M1 and macr

212 CTLA-4 blockade and granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting tumor vacci

213 nduced by exposure to granulocyte-macrophage colony-stimulating factor (GM-CSF).

214 h as IL-2, IL-15, and granulocyte-macrophage colony-stimulating factor (GM-CSF).

215 c hypersensitivity to granulocyte-macrophage colony-stimulating factor (GM-CSF).

216 bone marrow cells by granulocyte-macrophage colony-stimulating factor (GM-CSF)/G-CSF in vitro, inhib

217 Granulocyte macrophage colony-stimulating factor (GM-CSF, Csf2) is a growth fac

218 esized that targeting granulocyte-macrophage colony-stimulating factor (GM-CSF; an agonist cytokine l

219 [IL-10], IL-13, IL-6, granulocyte-macrophage colony-stimulating factor [GM-CSF], IL-4, and MIP-1alpha

220 for proinflammatory (granulocyte-macrophage colony-stimulating factor [GM-CSF], macrophage colony-st

221 ls of IL-1beta, IL-1alpha, IL-6, granulocyte-colony stimulating factor, granulocyte-macrophage colony

222 Human erythropoietin (hEPO) or granulocyte colony-stimulating factor (hGCSF) was independently fuse

223 ased the secretion of granulocyte macrophage-colony stimulating factor, IL-12, -13, and -15, which wa

224 ed significantly lower levels of granulocyte colony stimulating factor, IL-8, macrophage inflammatory

225 22, interferon-gamma, granulocyte macrophage colony-stimulating factor, IL-13).

226 m, and adjunctive treatment with granulocyte colony-stimulating factor in 1998.

227 and the pathophysiologic role of granulocyte colony-stimulating factor in exacerbation of preexisting

228 oclast precursors were induced by macrophage colony-stimulating factor in the presence of OEBFs, the

229 r of nuclear factor kappaB ligand/macrophage colony-stimulating factor induction of nuclear factor of

230 d chemokines, such as granulocyte macrophage colony-stimulating factor, interferon-gamma, interleukin

231 n-10, interleukin-17, granulocyte-macrophage colony-stimulating factor, interleukin-1beta, and interl

232 n beta subunit of the granulocyte-macrophage colony-stimulating factor/interleukin-3 receptor driving

233 omatography of recombinant human granulocyte colony stimulating factor is demonstrated.

234 Granulocyte-macrophage colony-stimulating factor is a potent stimulator of dend

235 Granulocyte-macrophage colony-stimulating factor is a potential therapeutic tar

236 crophage inflammatory protein-2, granulocyte colony-stimulating factor, keratinocyte chemoattractant)

237 on days 10-14; two cycles), with granulocyte-colony stimulating factor (lenograstim) support.

238 Macrophage colony stimulating factor (M-CSF) was implicated as a co

239 d macrophages differentiated with macrophage colony-stimulating factor (M-CSF) alone (termed M0) did.

240 togenesis medium with 20 ng/mL of macrophage colony-stimulating factor (M-CSF) and 50 ng/mL of recept

241 es of macrophages stimulated with macrophage colony-stimulating factor (M-CSF) and granulocyte-M-CSF

242 he molecular interactions between macrophage colony-stimulating factor (M-CSF) and the tyrosine kinas

243 r of NF-kappaB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF) as well as BMSC CM fro

244 Here, we investigated the role of macrophage colony-stimulating factor (M-CSF) in TAM differentiation

245 that monocytes differentiated by macrophage colony-stimulating factor (M-CSF) or granulocyte macroph

246 eroids (HDLS), which is caused by macrophage colony-stimulating factor (M-CSF) receptor mutations.

247 of hematopoietic progenitors with macrophage colony-stimulating factor (M-CSF) resulted in mTORC1-dep

248 factor (GM-CSF)-polarized M1 and macrophage colony-stimulating factor (M-CSF)-polarized M2, but not

249 macrophage glucose metabolism by macrophage colony-stimulating factor (M-CSF; inflammation resolving

250 48 serum cytokines and identified macrophage colony-stimulating factor (MCSF) as one of the elevated

251 data show that strategies targeting monocyte colony-stimulating factor (MCSF) signaling could be used

252 otericin B and another activator, macrophage colony-stimulating factor (MCSF), further elevated the r

253 lony-stimulating factor [GM-CSF], macrophage colony-stimulating factor [MCSF], interleukin-6 [IL-6],

254 of radiotherapy with granulocyte-macrophage colony-stimulating factor might result in abscopal respo

255 fludarabine plus cytarabine plus granulocyte colony-stimulating factor, mitoxantrone plus cytarabine,

256 (HCT), either marrow (n = 4) or granulocyte-colony stimulating factor mobilized peripheral blood ste

257 imary functional human MEPs from granulocyte colony-stimulating factor-mobilized peripheral blood and

258 se of mismatched, unrelated, and granulocyte colony-stimulating factor-mobilized peripheral blood ste

259 of immune cells contained within granulocyte colony-stimulating factor-mobilized peripheral blood ste

260 els of interleukin (IL)-6, IL-8, granulocyte colony-stimulating factor, monocyte chemoattractant prot

261 B-cell depletion or granulocyte-macrophage colony-stimulating factor neutralization inhibited DC an

262 tion of neutrophil functions via granulocyte colony-stimulating factor neutralization significantly d

263 plus blockade of the M2 cytokines macrophage colony-stimulating factor or MIF.

264 gand 5 (P < 0.01) and granulocyte-macrophage colony-stimulating factor (P < 0.001), thus contributing

265 sociated with elevated levels of granulocyte colony-stimulating factor (P = .02).

266 of clofarabine, cytarabine, and granulocyte-colony stimulating factor priming.

267 Filgrastim, an analog for granulocyte colony-stimulating factor produced by recombinant DNA te

268 of radiotherapy with granulocyte-macrophage colony-stimulating factor produced objective abscopal re

269 pregulated numbers of granulocyte-macrophage colony-stimulating factor-producing B cells within peric

270 Granulocyte macrophage colony-stimulating factor-producing IRA B cells alter ad

271 ron-gamma, IL-15, and granulocyte-macrophage colony-stimulating factor protected from subsequent mala

272 reduced responses to granulocyte-macrophage colony-stimulating factor, providing an additional mecha

273 mutations in CSF3R encoding the granulocyte colony-stimulating factor receptor (G-CSFR) in approxima

274 Mutations in the CSF3 granulocyte colony-stimulating factor receptor CSF3R have recently b

275 uency recurrent mutations in the granulocyte colony-stimulating factor receptor gene CSF3R, which sig

276 eporter mice (mice expressing the macrophage colony-stimulating factor receptor GFP transgene through

277 he Flt3 locus vs GM-CSF-alpha and macrophage-colony-stimulating factor receptor loci.

278 ncrease interleukin 3/granulocyte-macrophage colony-stimulating factor receptor signaling in bone mar

279 eptors (erythropoietin receptor, granulocyte colony-stimulating factor receptor, and MPL) whereas CAL

280 nd II cytokine receptors, except granulocyte colony-stimulating factor receptor, which supported only

281 Granulocyte-macrophage colony-stimulating factor-receptor-alpha expression patt

282 Granulocyte-macrophage colony-stimulating factor-receptor-alpha was predominant

283 d more surface IL-3 and granulocyte-monocyte colony-stimulating factor receptors, CD69, CD44, and CD2

284 ression of CSF2RB and granulocyte-macrophage colony-stimulating factor-responsive cells were defined

285 opria leukocytes with granulocyte-macrophage colony-stimulating factor resulted in high levels of pho

286 Restoring Cebpa expression by granulocyte colony-stimulating factor reverses the db phenotype and

287 to recombinant human granulocyte-macrophage colony stimulating factor (rhGM-CSF) (1 ng/mL for 6 h).

288 ing recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as a model drug, th

289 GVAX pancreas, granulocyte-macrophage colony-stimulating factor-secreting allogeneic pancreati

290 21, bone morphogenetic protein 7, macrophage colony-stimulating factor, stromal cell-derived factor-1

291 omodulatory adjuvants granulocyte-macrophage colony-stimulating factor, Toll-like receptor (TLR) liga

292 induced by GM-CSF, did not affect macrophage-colony-stimulating factor-triggered differentiation to m

293 ial cytokine response comprising granulocyte colony-stimulating factor, tumor necrosis factor alpha,

294 The protein therapeutic granulocyte-colony stimulating factor was analyzed using a Thermo Fu

295 Granulocyte colony-stimulating factor was prohibited.

296 s of IFN-gamma, IL-12, IL-6, and granulocyte colony-stimulating factor were significantly reduced, wh

297 Therapeutic colony-stimulating factors were associated with a 1.42-d

298 1r locus encodes the receptor for macrophage colony-stimulating factor, which controls the proliferat

299 ho were given inhaled granulocyte-macrophage colony-stimulating factor with first pulmonary recurrenc

300 r hypersensitivity to granulocyte-macrophage colony-stimulating factor with myeloid cell dysplasia an